Envoy Medical (COCH)
Develops fully implanted hearing devices that use the natural ear as a sound sensor.
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives. "The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Executive Officer of Envoy Medical.
Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build momentum with the hearing industry.
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submission marks the first regulatory milestone in the Company's planned modular PMA strategy.
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its common stock from time to time, has been terminated effective June 24, 2026.
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum Dates: June 24th & 25th Presentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m.
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas, NV Booth: #410 Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M.
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry. "As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems remains a key priority for Envoy Medical," said Brent Lucas, CEO, Envoy Medical.
Envoy Medical Appoints Chas McKhann to Board of Directors
Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful Exits White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors. Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder value.
Envoy Medical Reports Full Year 2025 Financial Results
Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 million in debt Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind fully implanted cochlear implant White Bear Lake, Minnesota--(Newsfile Corp. - March 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the full year ended December 31, 2025, as well as other subsequent events. Corporate and Financial Highlights for 2025: Received FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data Extinguished over $32 Million in Debt, Strengthening Balance Sheet Completed First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant Achieved Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial Highlights Subsequent to 2025 Year End: Completed enrollment of a 56-patient U.S. pivotal trial for the fully implanted Acclaim® Cochlear Implant Strengthened balance sheet with up to $78M public offering ($30M received, $48M potential from warrants) Expanded IP portfolio to 47 patents across North America, Europe, Asia, and Australia as of Feb. 20, 2026 Brent Lucas, CEO of Envoy Medical, commented: "We are extremely proud of the significant progress we made as a company in 2025, which included the FDA approval to expand our pivotal clinical trial to its final stage.
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry. "We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical.
Analyzing Envoy Medical (NASDAQ:COCH) and TearLab (OTCMKTS:TEAR)
TearLab (OTCMKTS:TEAR - Get Free Report) and Envoy Medical (NASDAQ: COCH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Profitability This table compares TearLab and Envoy Medical's net
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25 th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanter White Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today provided a business update highlighting its recent transformative financing led by long-term institutional investors and existing shareholders, noting further positive clinical trial progress, and announcing an upcoming fireside chat.
Envoy Medical (NASDAQ:COCH) Major Shareholder Glen Taylor Buys 18,750,000 Shares of Stock
Envoy Medical, Inc. (NASDAQ: COCH - Get Free Report) major shareholder Glen Taylor acquired 18,750,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were bought at an average price of $0.40 per share, with a total value of $7,500,000.00. Following the completion of the transaction, the insider directly owned 21,703,607 shares
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cash Offering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and management Net proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone-linked warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond first full year of commercialization White Bear Lake, Minnesota--(Newsfile Corp. - February 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the closing of its previously announced upsized public offering of an aggregate of 75,000,000 shares of its Class A common stock (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 45,000,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series A-2 common warrants to purchase up to 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu thereof), at a combined public offering price of $0.40 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants. "We are pleased to have closed this transformational financing anchored by Nantahala Capital and with strong support from Glen Taylor, other healthcare funds, and several members of the Board of Directors and management.
Envoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5
WHITE BEAR LAKE, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today announced that management will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026.
Envoy Medical Secures New Australian Patent for Cochlear Implant Innovation Aimed at Enhancing Input Signal-to-Noise Ratio
White Bear Lake, Minnesota--(Newsfile Corp. - December 16, 2025) - Envoy Medical Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"),
Envoy Medical, Inc. (COCH) Upgraded to Buy: Here's Why
Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Envoy Medical Announces the Grant of Its 40th U.S. Patent
New Patent Adds to Company's Growing Portfolio of Intellectual Property Focused on Fully Implanted Hearing Devices White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents.